Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000187510 | SCV000241104 | uncertain significance | not provided | 2015-01-14 | criteria provided, single submitter | clinical testing | p.Val162Met (GTG>ATG): c.484 G>A in exon 7 of the GABRA1 gene (NM_000806.5). The V162M variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. It was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The V162M variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. In addition, other missense mutations in nearby residues have not been reported in association with GABRA1-related disorders. However, this substitution occurs at a position that is conserved, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. The variant is found in EPILEPSYV2-1 panel(s). |